Interest of Famotidine in Reducing Endothelial Expression of P-selectin in Children With Sickle Cell Disease: Pilot Study, Single-center, Prospective, Non-comparative.

About the study

The purpose of this study is to determine whether oral famotidine, a histamine type 2 receptor antagonist already widely used with very few side effects in other indications in children, is effective in reducing endothelial expression of P-selectin in children with sickle cell disease (SCD).

This pilot study will constitute the essential prerequisite for a randomized clinical trial comparing the efficacy of famotidine with that of placebo in the prevention of vaso-occlusive crises in SCD patients.

Study point of contact

Slimane ALLALI, MD, PhD
+33-(0)1-44-49-48-96
[email protected]
Prissile BAKOUBOULA, PhD
+33-(0)1-71-19-64-94
[email protected]

Locations

1 France site

Age

1 Year - 17 Years

Phase

Phase 2/Phase 3

Study type

Interventional

Gender

All

Interventions

Drug

participation requirements

child or adolescent aged 1 year to 17 years and 10 months, followed at the Necker-Enfants malades Hospital for a SS or Sβ0 SCD;
having at least one vaso-occlusive crisis in the year prior to inclusion;
for young girl of childbearing age (≥ 15 years old), a negative pregnancy test;
signed informed consent of the 2 parents or legal representative(s) and of the child of expressive age or the adolescent;
beneficiary of social security coverage or entitled (excluding AME)

participation restrictions

treatment with crizanlizumab (anti-P-selectin antibody);
treatment with atazanavir/ritonavir in combination with tenofovir;
known hypersensitivity to famotidine or to other histamine type 2 (H2) receptor antagonists;
cardiovascular history such as: arrhythmia, AVB (atrioventricular block), QT prolongation;
renal failure characterized by creatinine clearance <60 mL/min; hepatic cytolysis (ALT ≥ 3N); neutropenia (<1 G/L), thrombocytopenia (<80 G/L), reticulopenia (<80 G/L); predictable poor adherence to treatment; pregnancy or breastfeeding; participation in another interventional research involving the human person; planned bone marrow transplant or gene therapy within one month of inclusion. Within 3 months prior to inclusion: red blood cell transfusion; introduction of hydroxyurea or modification of hydroxyurea doses; introduction of L-glutamine or modification of L-glutamine doses; introduction of voxelotor or modification of voxelotor doses; taking oral or IV corticosteroids or any other immunomodulatory treatment; taking an antihistamine treatment In the month preceding inclusion: occurrence of a vaso-occlusive crisis, acute chest syndrome or any vaso-occlusive phenomenon (acute splenic sequestration, priapism, stroke, occlusion of the central retinal artery, papillary necrosis); occurrence of fever (≥ 38°C) or any infectious episode, febrile or not, suspected or confirmed, of a viral, bacterial, fungal or parasitic nature ; occurrence of an acute hemolytic episode (increase in jaundice and pallor, decrease in hemoglobin level of ≥ 1 g/dL compared to baseline hemoglobin, increase in LDH and/or AST and/or free bilirubin deemed significant by the child's referring physician).

Locations

  • Paris, France, Necker - Enfants malades Hospital; Department of Pediatrics and Infectious Diseases
Last updated 2022-02-09